Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
AMRQ, ECR, GMET, ABDX, LIFS, TEK, OPTI, PREM, KOD, BRES, TYM & AVCT could constitute the 12 best small caps to watch in Q4 2023.
The FTSE AIM market has fallen in value by a third over the past five years, and 12% in 2023 alone.
AstraZeneca (LON:AZN) reaches a monthly peak due to positive outcomes from a breast cancer medication trial.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
OptiBiotix Health (AIM:OPTI) Planned launch of OptiBiotix products with Boots
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator I Patent Portfolio Strengthened
Notice of allowance for patent grant in Japan
Scancell Holdings (AIM:SCLP OTC:SCNLF) jump 23% following trial data; analysts praise the outcomes
Scancell Holdings PLC (AIM: SCLP, OTC: SCNLF) shares soared by 23% in early market hours after it reported that the initial phase of its phase II SCOPE trial for advanced
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family
Avacta Group PLC (AIM:AVCT) Successful Completion of Sixth Dose Escalation
Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
Hemogenyx Pharma Plc (AIM:HEMO) Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
hVIVO PLC (AIM:HVO) Interim results
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance